Case Report: The effective treatment of patients in advanced no-small cell lung cancer patients with EGFR G719X/S768I/L861Q and acquired MET amplification: A case series and literature review

Yun Zhao; Cuiyun Su; Lina Shi; Wenqi Luo; Zhen Liu; Chuqiao Liang; Huilin Wang; Ruiling Ning; Qitao Yu; Wei Jiang

doi:10.3389/fonc.2023.1126325

Case Report: The effective treatment of patients in advanced no-small cell lung cancer patients with EGFR G719X/S768I/L861Q and acquired MET amplification: A case series and literature review

Front Oncol. 2023 Feb 22:13:1126325. doi: 10.3389/fonc.2023.1126325. eCollection 2023.

Authors

Yun Zhao¹, Cuiyun Su¹, Lina Shi², Wenqi Luo³, Zhen Liu⁴, Chuqiao Liang², Huilin Wang¹, Ruiling Ning¹, Qitao Yu¹, Wei Jiang¹

Affiliations

¹ Department of Medical Oncology of Respiratory, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
² Medical Department, Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, China.
³ Department of Pathology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
⁴ Department of Anesthesiology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.

Abstract

Preclinical cases suggest that EGFR tyrosine kinase inhibitors (TKIs) plus MET TKIs are a potential therapy for non-classical EGFR mutant lung cancers with MET amplification acquired resistance. Herein, we report for the first time the effectiveness of novel combination treatment regimens for patients with EGFR G719X/S768I/L861Q. Until the last follow-up assessment, two patients demonstrated improved survival after they switched to afatinib combined with savolitinib (PFS: 10 months) and furmonertinib combined with crizotinib (PFS: 6 months), respectively, that did not observed increased incidence and severity of adverse events. According to the findings of this study and literature review, various responses were observed from the combined therapy in NSCLC patients who harbored uncommon EGFR mutations and MET amplification. Furthermore, Next generation sequencing (NGS) leads to the discovery of uncommon of EGFR and reveals the co-mutations in NSCLC.

Keywords: EGFR G719X/S768I/L861Q; MET amplification; non-small cell lung cancer (NSCLC); resistance; uncommon mutation.

Publication types

Case Reports

Grants and funding

This work were supported by the Promoting Project of Basic Capacity for Young and Middle-aged University Teachers in Guangxi, China (no.2021KY0098), and Guangxi Medical and health key discipline construction project.